# Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection

> **NCT04044651** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Shi Ming**

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Lenvatinib
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04044651
- **Lead sponsor:** Shi Ming
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-10-30
- **Primary completion:** 2021-03-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Bristol-Myers Squibb company terminated this study
- **Last updated:** 2020-01-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04044651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04044651, "Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04044651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*